Stocks & Investing
Stocks and Investing
Stocks and Investing
Tue, August 6, 2024
[ Tue, Aug 06th 2024
] - WOPRAI
[ Tue, Aug 06th 2024
] - WOPRAI
[ Tue, Aug 06th 2024
] - WOPRAI
[ Tue, Aug 06th 2024
] - WOPRAI
[ Tue, Aug 06th 2024
] - WOPRAI
[ Tue, Aug 06th 2024
] - WOPRAI
[ Tue, Aug 06th 2024
] - WOPRAI
[ Tue, Aug 06th 2024
] - WOPRAI
[ Tue, Aug 06th 2024
] - WOPRAI
[ Tue, Aug 06th 2024
] - WOPRAI
[ Tue, Aug 06th 2024
] - WOPRAI
[ Tue, Aug 06th 2024
] - WOPRAI
[ Tue, Aug 06th 2024
] - WOPRAI
[ Tue, Aug 06th 2024
] - WOPRAI
[ Tue, Aug 06th 2024
] - WOPRAI
[ Tue, Aug 06th 2024
] - WOPRAI
[ Tue, Aug 06th 2024
] - WOPRAI
[ Tue, Aug 06th 2024
] - WOPRAI
[ Tue, Aug 06th 2024
] - WOPRAI
[ Tue, Aug 06th 2024
] - WOPRAI
[ Tue, Aug 06th 2024
] - WOPRAI
[ Tue, Aug 06th 2024
] - WOPRAI
[ Tue, Aug 06th 2024
] - WOPRAI
[ Tue, Aug 06th 2024
] - WOPRAI
Etzer Darout Reiterated (CCCC) at Buy and Held Target at $20 on, Aug 6th, 2024
Etzer Darout of BMO Capital, Reiterated "C4 Therapeutics, Inc." (CCCC) at Buy and Held Target at $20 on, Aug 6th, 2024.
Etzer has made no other calls on CCCC in the last 4 months.
There are 2 other peers that have a rating on CCCC. Out of the 2 peers that are also analyzing CCCC, 1 agrees with Etzer's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Derek Archila of "Wells Fargo" Maintained at Hold with Increased Target to $8 on, Thursday, May 9th, 2024
This is the rating of the analyst that currently disagrees with Etzer
- Bradley Canino of "Stifel" Maintained at Strong Buy with Increased Target to $14 on, Thursday, May 9th, 2024
